Teva’s UK subsidiary has joined forces with techbio company Closed Loop Medicine to use its software as a medical device (SaMD) technology platform in the development of new personalised medicines.

Teva的英国子公司与techbio公司Closed Loop Medicine联手，将其软件用作医疗设备（SaMD）技术平台，用于开发新的个性化药物。

Details of the alliance are sparse at the moment, but the two companies have revealed that they are looking at ways to improve drug efficacy and outcomes in patients with specific chronic disorders by combining dose-optimised drug therapy with digital care.

目前联盟的细节尚不多见，但两家公司透露，他们正在寻找将剂量优化药物治疗与数字护理相结合的方法，以提高特定慢性疾病患者的药物疗效和预后。

The companies envisage combining Closed Loop’s SaMD – which has shown its worth in a recently reported hypertension clinical trial – as “digital companions” that would be prescribed alongside Teva’s pharmaceutical products.

这些公司设想将闭环的SaMD（在最近报道的高血压临床试验中显示出其价值）结合起来，作为“数字伴侣”，与Teva的药品一起使用。

In the PERSONAL-CovidBP trial of Closed Loop’s smartphone-based CL-HT01 software, the SDaMD was shown to deliver improved blood pressure control and adherence to therapy as well as reduced side effects in patients using it to manage their antihypertensive drug treatment.

在Closed Loop基于智能手机的CL-HT01软件的个人CovidBP试验中，SDaMD被证明可以改善血压控制和治疗依从性，并减少使用它来管理抗高血压药物治疗的患者的副作用。

“As clinicians, we know that dosing of drugs is a huge problem,” said Dr Paul Goldsmith, co-founder and president of Closed Loop Medicine who also serves as the company’s chief medical officer and innovation officer.

“作为临床医生，我们知道给药是一个巨大的问题，”闭环医学联合创始人兼总裁保罗·戈德史密斯博士说，他也是该公司的首席医疗官和创新官。

“In the most extreme cases, we are seeing patients having severe adverse events, for example when required to change dose levels to undergo surgery,” he added. “Being able to predict personalised dose levels could be transformational.”

他补充说：“在最极端的情况下，我们看到患者出现严重的不良事件，例如需要改变剂量水平才能进行手术。”。“能够预测个性化剂量水平可能会带来变革。”

Applying the technology to Teva’s established and new medicines could help to improve their effectiveness in the real world, according to the partners.

根据合作伙伴的说法，将该技术应用于Teva的既有药物和新药可能有助于提高其在现实世界中的有效性。

Personalised medicine is a term that has become a mantra in pharma, promising better outcomes for patients, but definitions vary and it is still something of a nebulous concept.

个性化药物这个术语已经成为制药界的一个口号，它承诺为患者带来更好的结果，但定义各不相同，它仍然是一个模糊的概念。

Closed Loop was set up to address the fact that most medicines are still prescribed based on their average effects in a population and rarely dose optimised for the individual, in a “one-size-fits-all” approach, recognising that personalisation remains an aspiration rather than a reality in many health settings.

建立闭环是为了解决这样一个事实，即大多数药物仍然是根据其在人群中的平均作用开具的，很少针对个人进行剂量优化，采用“一刀切”的方法，认识到个性化仍然是一种愿望，而不是在许多健康环境中的现实。

The Cambridge-based company points out that the cost of dealing with side effects of medicines in the NHS is estimated at more than £2.2 billion ($2.8 billion), while in the US a figure of $428 billion was given to the cost of managing drug-related morbidity and mortality resulting from non-optimised medication in 2016.

这家总部位于剑桥的公司指出，NHS处理药物副作用的成本估计超过22亿英镑（28亿美元），而在美国，2016年管理非优化药物导致的药物相关发病率和死亡率的成本为428亿美元。

Teva’s general manager for the UK & Ireland, Kim Innes, commented that the company is aware “the patient experience can sometimes be less than optimal,” just ahead of a new survey indicating that public satisfaction with the NHS is at its lowest level in decades.

Teva英国和爱尔兰总经理Kim Innes评论说，在一项新的调查表明公众对NHS的满意度处于几十年来的最低水平之前，该公司意识到“患者体验有时可能不太理想”。

“As the largest supplier of medicines to the NHS, the potential to combine ‘drug’ & ‘digital’ could create significant improvements to lives of patients at great scale,” she added.

她补充说：“作为NHS最大的药物供应商，将“药物”和“数字”结合起来的潜力可能会大大改善患者的生活。”